Dymicron®, a privately held medical device company pioneering advanced spinal technologies, today announced the successful enrollment and treatment of the first patient in its Triadyme®-C Investigational Device Exemption (IDE) clinical trial. This milestone marks the initiation of a U.S. clinical study evaluating the safety and effectiveness of the Triadyme-C cervical artificial disc.

Dymicron®, a pioneering medical technology company renowned for its revolutionary cervical spine disc replacement solution, has announced the appointment of Dominik Wilke as its new Senior Manager, Business Development and Marketing. With over a decade of experience in the spinal device industry, Dominik brings a wealth of expertise and a passion for innovation to his new...